Comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis

The growing number of antihuman epidermal growth factor receptor-2 (HER2) agents suggests the need for defining the optimal choice of neoadjuvant therapy for HER2-positive breast cancer. This study aims to assess the efficacy and safety of neoadjuvant therapy for HER2-positive breast cancer. Randomi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JNCI : Journal of the National Cancer Institute 2014-09, Vol.106 (9), p.1
Hauptverfasser:	Nagayama, Aiko, Hayashida, Tetsu, Jinno, Hiromitsu, Takahashi, Maiko, Seki, Tomoko, Matsumoto, Akiko, Murata, Takeshi, Ashrafian, Hutan, Athanasiou, Thanos, Okabayashi, Koji, Kitagawa, Yuko
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal, Humanized - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bayes Theorem Biomarkers, Tumor - analysis Biomarkers, Tumor - antagonists & inhibitors Breast cancer Breast Neoplasms - chemistry Breast Neoplasms - drug therapy Chemotherapy Clinical trials Comparative Effectiveness Research Epidermal growth factor Female Humans Meta-analysis Middle Aged Neoadjuvant Therapy - methods Odds Ratio Protein Kinase Inhibitors - therapeutic use Quinazolines - administration & dosage Quinazolines - adverse effects Receptor, ErbB-2 - analysis Receptor, ErbB-2 - antagonists & inhibitors Trastuzumab
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!